These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10737478)

  • 1. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.
    Pariente JL; Bordenave L; Jacob F; Gobinet A; Leger F; Ferriere JM; Le Guillou M
    J Urol; 2000 Apr; 163(4):1116-9. PubMed ID: 10737478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
    Pariente JL; Bordenave L; Michel P; Latapie MJ; Ducassou D; Le Guillou M
    J Urol; 1997 Aug; 158(2):338-41. PubMed ID: 9224298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
    J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
    el-Ahmady O; Halim AB; el-Din AG
    Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
    Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
    J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
    J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical usefulness of urinary determinations of cytokeratin 19 fragment (CYFRA 21-1) in urothelial tumor].
    Takeuchi S; Saitoh H; Yoshida K; Satake I; Tari K
    Hinyokika Kiyo; 1995 Aug; 41(8):589-92. PubMed ID: 7572437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
    Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
    J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder.
    Satyam A; Singh P; Sharma M; Seth A; Sharma A
    Biomarkers; 2011 Aug; 16(5):413-21. PubMed ID: 21777169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer.
    Sánchez-Carbayo M; Espasa A; Chinchilla V; Herrero E; Megías J; Mira A; Soria F
    Clin Chem; 1999 Nov; 45(11):1944-53. PubMed ID: 10545064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer.
    Morita T; Kikuchi T; Hashimoto S; Kobayashi Y; Tokue A
    Eur Urol; 1997; 32(2):237-44. PubMed ID: 9286660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.